[Therapy of subacute sclerosing panencephalitis with intrathecal alpha-interferon].
Clinical benefits were noted in subacute sclerosing panencephalitis patients treated with a total of 15 x 10(6) I.U. of alpha-interferon administered intrathecally over a period of one month. Improvements did not correlate with major variations in anti-measles IgG titers or variation of pattern, IgG subclass or light chain composition of CSF oligoclonal bands.
L M
LM
Grimaldi
D
D
Maimone
D000293:Adolescent; D002648:Child; D006801:Humans; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid; D007278:Injections, Spinal; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D013344:Subacute Sclerosing Panencephalitis / Q000134:cerebrospinal fluid / Q000628:therapy*
D007074:Immunoglobulin G; D007370:Interferon Type I
Terapia della panencefalite sclerosante subacuta con alfa-interferon intratecale.